Showing results (31-40 of 48) with videos related to
Sort By:
Pageof 5
Journal of Medicinal Chemistry|September 6, 2002
Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groupsMichael C Pirrung, L Nathan Tumey, Christian R H Raetz, et al.Bioorganic & Medicinal Chemistry Letters|September 19, 2009
First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitorsChuansheng Niu, Diane H Boschelli, L Nathan Tumey, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 13, 2024
A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkersMeghan E Gray, Karina M Zielinski, Fanny Xu, et al.Journal of Medicinal Chemistry|November 21, 2025
Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor ActivityVictor T Ojo, Nicholas A Bianchi, Michele Z Yi, et al.Plos One|May 31, 2017
Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugateSujiet Puthenveetil, Haiyin He, Frank Loganzo, et al.Bioorganic & Medicinal Chemistry Letters|September 3, 2004
The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitorsL Nathan Tumey, Bayard Huck, Elizabeth Gleason, et al.Bioorganic & Medicinal Chemistry Letters|December 18, 2004
The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitorsL Nathan Tumey, David Bom, Bayard Huck, et al.Antimicrobial Agents and Chemotherapy|May 26, 2006
Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosaKhisimuzi E Mdluli, Pamela R Witte, Toni Kline, et al.Bioorganic & Medicinal Chemistry Letters|April 15, 2014
Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4L Nathan Tumey, Diane H Boschelli, Niala Bhagirath, et al.The AAPS Journal|April 26, 2017
Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug ConjugatesL Nathan Tumey, Fengping Li, Brian Rago, et al.Pageof 5